SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma receives USFDA Approval for Entacapone Tablets

22 Jun 2015 Evaluate

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Entacapone Tablets USP, 200mg (ANDA 203437). The product will be launched soon. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Comtan Tablets 200mg of Orion Corporation.

Entacapone Tablets are used in the treatment of Parkinson's disease and has an estimated market size of US$59 Million for the twelve months ending April 2015 according to IMS. This is the 39th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products. 

Aurobindo Pharma Share Price

1380.30 -5.35 (-0.39%)
20-Apr-2026 11:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.60
Dr. Reddys Lab 1237.20
Cipla 1235.85
Zydus Lifesciences 941.30
Lupin 2323.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×